PTCT (PTCT) Stock Analysis
Verdict: HOLD
Commercial rare-disease cash flow de-risks pipeline, but $2.7B debt and restructuring-driven margin volatility cap near-term upside.
Investment score: 58/100
The model evaluates PTCT as a Hold at $68.22. Solid commercial rare-disease revenue and positive earnings beats are counterbalanced by a $2.71B debt burden and persistent insider selling.
Peers
| Peer | P/E | P/B | P/S | EV/EBITDA | ROIC % | Net margin % |
|---|---|---|---|---|---|---|
| ORKA | -39.26 | 5.47 | 0.00 | -39.41 | — | 0.00 |
| SRRK | -15.03 | 25.60 | 0.00 | -14.45 | — | 0.00 |
| TVTX | -144.42 | 247.75 | 10.22 | 4237.55 | — | -0.07 |
| DNTH | -794.88 | 4.94 | 3035.70 | -192.16 | — | -15.71 |
| COGT | -14.49 | 10.75 | 0.00 | -15.51 | — | 0.00 |